ArticleJournal of Ayurveda and integrative medicine
Exploring the pharmacokinetic interactions between cisplatin and Triphala through in-vitro, in-vivo, and in-silico approaches - A pilot study to bridge modern medicine with Ayurveda.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerbal drugs are often used alongside conventional cancer therapies to mitigate the adverse effects and enhance therapeutic efficacy. Triphala, a traditional herbal formulation used in Ayurveda, is known for its anticancer and CYP2E1 inhibitory properties. Cisplatin, although highly effective in cancer treatment, is known to cause significant hepatotoxicity and nephrotoxicity which are mediated by toxic metabolites formed through CYP2E1 metabolism.
objectiveThe objective of this study is to explore the pharmacokinetic drug interactions between Triphala and cisplatin.
methodsAt the outset, the pharmacokinetic interactions between Triphala and cisplatin were confirmed by in-vitro experiments using HepG2 and 786-0 cell lines based on Reactive Oxygen Species (ROS) generation and cell viability assay, and in-vivo study using Sprague Dawley rats based on serum cisplatin concentration. Later, the literature derived phytoconstituents were subjected to in-silico studies to investigate their molecular interactions with the metabolizing enzyme CYP2E1.
resultsIn-vitro studies revealed a reduction in ROS generation and enhanced cell viability, indicating that the metabolism of cisplatin is hindered by Triphala, which was attributed to its CYP2E1 inhibitory potential. In-vivo studies showed a marginal increase in cisplatin concentrations in rat serum that received the combination of Triphala and cisplatin, supporting the in-vitro findings. In-silico studies revealed that Triphala constituents, especially gallic acid and 3,5-dihydroxy-4-methoxybenzoic acid, stably bind and potentially inhibit CYP2E1 via key interactions with THR303.
conclusionThe results suggest that Triphala may interact with cisplatin by inhibiting the CYP2E1 enzyme, potentially affecting the metabolism and toxicity of cisplatin. These findings highlight the need for further research to evaluate the clinical implications of using Triphala alongside cisplatin-based cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.